Search
Results

The federal 340B Drug Pricing Program continues to be an important source of funding for vital patient care as covered entities face rising healthcare costs, reimbursement cuts, and uncompensated care. 340B is a significant part of an increasingly complex pharmacy supply chain, requiring solutions designed to help providers manage compliance and reporting compliance, while capturing drug cost savings. Technology-driven 340B management is also a key component of Autonomous Pharmacy, an industry vision for zero-error medication management through automation, intelligence, and technology enabled services.

Expanded capabilities for retail/specialty pharmacy management and 340B program administration help to maximize revenue and savings across all patient care settings.

Get updates on how policy and legal developments could impact the 340B Drug Pricing Program.

As a source of funding for vital patient care, the Federal 340B Drug Pricing Program is as important as ever. It also can be increasingly complicated with frequent changes in compliance and reporting requirements.

Imagine if there was a way to resolve two of the most intractable challenges in the 340B program in one fell swoop: one that has a significant impact on the financial health of 340B providers, and another that affects the pharmaceutical industry’s bottom line? It may be hard to imagine, but there is now a bill in Congress that can be welcomed by both the 340B covered entity community and the drug industry.

After a long period of treading water, recent developments in federal court bode well for 340B providers trying to restore access to 340B pricing in the contract pharmacy setting. A close review of recent government court filings also provides a strong endorsement for a key but highlydebated tenet of the 340B program.

HRSA’s supposed lack of authority to enforce its 340B guidance is central to the recent debate over the contract pharmacy program. With a new administration, we should expect to see stronger enforcement from HRSA, as well as the possibility of new guidance.

Recently the Supreme Court ruled 9-0 that the federal government unlawfully slashed Medicare Part B drug reimbursement for 340B hospitals by almost 30 percent during 2018 and 2019. See what this means for the program from Ted Slafsky with the 340B Report.

Mounting pharmaceutical manufacturer restrictions and political uncertainty are currently disrupting the 340B landscape. In the face of this adversity, the 340B Coalition Summer Conference demonstrated how the 340B program meets the needs of vulnerable patients today while funding programs to improve the ongoing health and wellness of these communities going forward.

Since the Affordable Care Act (ACA) was enacted a decade ago, most 340B provider advocates have preached caution, as 340B providers scored significant victories in the ACA. These wins included expanding the 340B program to include rural hospitals, increasing pricing transparency and providing additional oversight over drug manufacturers. Ever since, 340B advocates have been largely playing defense – reacting, rather than setting the agenda.